Abstract
Shortly after the discovery of liposomes (J Mol Biol 13:238–252, 1965), Gregoriadis et al. (Lancet 1:1313–1316, 1974) suggested their use as drug delivery vesicles. Since then there have been many developments in liposomal composition, efficient drug encapsulation and retention, stability, and targeting (Biochim Biophys Acta 1113:171–199, 1992). However, even though some of the very potent drug formulations in liposomes were clinically approved, in most cases the amount of drug passively released from such ideal, long-circulating, sterically stable liposomes was not enough to show a therapeutic effect (Cancer Chemother Pharmacol 49:201–210, 2002; Cancer Chemother Pharmacol 48:266–268, 2001; Eur J Cancer 37:2015–2022, 2001; Breast Cancer Res Treat 77:185–188, 2003; Lung Cancer 34:427–432, 2001; Cancer Chemother Pharmacol 50:131–136, 2002). It has been hypothesized that the enhanced release at the target site will significantly improve the specificity and efficacy of a liposomal drug (J Liposomes Res 8:299–335, 1998; Pharmaco Rev 51:691–744, 1999; Curr Opin Mol Ther 3:153–158, 2001). To solve this challenge, more research efforts were directed toward a triggered release, in response to a specific stimulus at a target site. Here, we present an engineered, bacterial channel protein as a remote-controlled nanovalve in sterically stable liposomes for a triggered release of the liposomal content on command.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238–252
Gregoriadis G, Wills EJ, Swain CP, Tavill AS (1974) Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1:1313–1316
Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171–199
Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A et al (2002) Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 49:201–210
Thomas AL, O’Byrne K, Furber L, Jeffery K, Steward WP (2001) phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemother Pharmacol 48:266–268
Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JSW (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37:2015–2022
Rimassa L, Carnaghi C, Garassino I, Salvini P, Ginanni V, Gullo G et al (2003) Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 77:185–188
Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D et al (2001) A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34:427–432
Vail DM, Kurzman ID, Glawe PC, O’Brien MG, Chun R, Garrett LD et al (2002) STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 50:131–136
Bally MB, Lim H, Cullis PR, Mayer LD (1998) Controlling the drug delivery attributes of lipidbased drug formulations. J Liposomes Res 8:299–335
Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmaco Rev 51:691–744
Fenske DB, MacLachlan L, Cullis PR (2001) Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther 3:153–158
Guo X, Szoka FC (2003) Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc Chem Res 36:335–341
Kocer A, Walko M, Meijberg W, Feringa BL (2005) A light-actuated nanovalve derived from a channel protein. Science 309:755–758
Kocer A, Walko M, Bulten E, Halza E, Feringa BL, Meijberg W (2006) Rationally designed chemical modulators convert a bacterial channel protein into a pH-sensory valve. Angew Chem Int Ed Engl 45:3126–3130
Kocer A, Walko M, Feringa BL (2007) Synthesis and Utilization of reversible and irreversible light activated nanovalves derived from the channel protein MscL. Nat Protoc 2:1426–1437
Andresen TL, Jensen SS, Jorgensen K (2005) Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–97
Delcour AH, Martinac B, Adler J, Kung C (1989) Modified reconstitution method used in patch-clamp studies of Escherichia coli ion channels. Biophys J 56:631–636
Sukharev SI, Blount P, Martinac B, Blattner FR, Kung C (1994) A large-conductance mechanosensitive channel in E. coli encoded by mscL alone. Nature 368:265–268
Perozo E, Cortes DM, Sompornpisut P, Kloda A, Martinac B (2002) Open channel structure of MscL and the gating mechanism of mechanosensitive channels. Nature 418:942–948
Perozo E, Kloda A, Cortes DM, Martinac B (2002) Physical principles underlying the transduction of bilayer deformation forces during mechanosensitive channel gating. Nature Struct Biol 9:696–703
Van den Bogaart G, Krasnikov V, Poolman B (2007) Dual-colo fluorescence-burst analysis to probe protein efflux through the mechanosensitive channel. MscL Biophys J 92:1233–1240
Sukharev S, Anishkin A (2004) Mechanosensitive channels: what can we learn from ‘simple’ model systems? Trends Neurosci 27:345–351
Anishkin A, Chiang CS, Sukharev S (2005) Gain-of-function mutations reveal expanded intermediate states and a sequential action of two gates in MscL. J Gen Physiol 125:155–170
Yoshimura K, Batiza A, Kung C (2001) Chemically charging the pore constriction opens the mechanosensitive channel MscL. Biophys J 80:2198–2206
Acknowledgments
The author would like to thank Professor George Robillard for his critical reading of the chapter. This work was supported by Biomade Technology Foundation, NanoNed, and The Netherlands Organization for Scientific Research (NWO-VIDI).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Koçer, A. (2010). Functional Liposomal Membranes for Triggered Release. In: Weissig, V. (eds) Liposomes. Methods in Molecular Biology, vol 605. Humana Press. https://doi.org/10.1007/978-1-60327-360-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-60327-360-2_16
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-359-6
Online ISBN: 978-1-60327-360-2
eBook Packages: Springer Protocols